Analyst Eliana Merle of UBS maintained a Buy rating on Alnylam Pharma, retaining the price target of $550.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eliana Merle’s rating is based on several positive aspects of Alnylam Pharma’s recent developments. Despite the KARDIA-3 study not meeting its primary statistical significance, the results showed a meaningful reduction in blood pressure when zilebesiran was used alongside standard care. The sustained blood pressure control, particularly at night, and the enhanced effects observed in patients using diuretics, highlight zilebesiran’s potential in managing hypertension effectively.
Furthermore, the clean safety profile and the potential for improved patient adherence due to the biannual dosing schedule make zilebesiran a promising candidate in the hypertension market. Additionally, Alnylam’s ongoing efforts in launching Amvuttra for ATTR-CM present a significant growth opportunity, with the potential to tap into a market valued at approximately $10 billion. These factors collectively support the Buy rating, indicating a strong belief in Alnylam’s future prospects and market potential.
Merle covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Ascendis Pharma, and Alnylam Pharma. According to TipRanks, Merle has an average return of -4.1% and a 40.98% success rate on recommended stocks.
In another report released yesterday, Citi also maintained a Buy rating on the stock with a $583.00 price target.